These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 31713168)

  • 1. Immuno-Oncology in the Era of Personalized Medicine.
    Gwin WR; Disis ML; Ruiz-Garcia E
    Adv Exp Med Biol; 2019; 1168():117-129. PubMed ID: 31713168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
    Music M; Prassas I; Diamandis EP
    Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
    Golan T; Milella M; Ackerstein A; Berger R
    J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
    Mandal R; Chan TA
    Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cancer: three eras of personalized medicine].
    Jordan B
    Med Sci (Paris); 2017 Oct; 33(10):905-908. PubMed ID: 28994388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology.
    Giraldo NA; Peske JD; Sautès-Fridman C; Fridman WH
    Virchows Arch; 2019 Apr; 474(4):463-474. PubMed ID: 30631935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision medicine in pediatric oncology.
    Forrest SJ; Geoerger B; Janeway KA
    Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine.
    Capella MP; Esfahani K
    Curr Oncol; 2024 Apr; 31(4):1913-1919. PubMed ID: 38668046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer subtypes: morphologic and biologic characterization.
    Masood S
    Womens Health (Lond); 2016 Jan; 12(1):103-19. PubMed ID: 26756229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional MR Imaging Techniques in Oncology in the Era of Personalized Medicine.
    Benz MR; Vargas HA; Sala E
    Magn Reson Imaging Clin N Am; 2016 Feb; 24(1):1-10. PubMed ID: 26613872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass spectrometry based proteomics and metabolomics in personalized oncology.
    Kowalczyk T; Ciborowski M; Kisluk J; Kretowski A; Barbas C
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165690. PubMed ID: 31962175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
    Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
    Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art.
    Butterfield LH; Disis ML; Fox BA; Kaufman DR; Khleif SN; Wang E;
    J Immunother Cancer; 2018 Dec; 6(1):138. PubMed ID: 30514399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized Medicine in Gynecologic Cancer: Fact or Fiction?
    Corey L; Valente A; Wade K
    Obstet Gynecol Clin North Am; 2019 Mar; 46(1):155-163. PubMed ID: 30683261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends and challenges in immuno-oncology trials.
    Kiernan B
    Drugs Today (Barc); 2016 Jul; 52(7):387-93. PubMed ID: 27540597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development.
    Beckman RA; Chen C
    Adv Exp Med Biol; 2015; 867():81-90. PubMed ID: 26530361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Medicine in Gynecologic Cancer: Fact or Fiction?
    Corey L; Valente A; Wade K
    Surg Oncol Clin N Am; 2020 Jan; 29(1):105-113. PubMed ID: 31757307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Signature Program: Bringing the Protocol to the Patient.
    Kang BP; Slosberg E; Snodgrass S; Lebedinsky C; Berry DA; Corless CL; Stein S; Salvado A
    Clin Pharmacol Ther; 2015 Aug; 98(2):124-6. PubMed ID: 25810246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing precision cancer medicine in the genomic era.
    Chen HZ; Bonneville R; Roychowdhury S
    Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.